Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the management of early-stage triple-negative breast cancer (TNBC), highlighting real-world trends and prognosis in the use of chemotherapy for patients with stage IA TNBC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
